Update date
31 Dec 2025
Shareable Research Card
ABVX - Abivax S.A. Research And Development Expense
This metric view shows ABVX - Abivax S.A. research and development expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2025
- Latest reported value
- €44,399,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2025.
- Latest reported value on this page: €44,399,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Research And Development Expense
Latest reported research and development expense: €44,399,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 23 Mar 2026.
Benchmark Context
How Research And Development Expense compares with peers
Abivax S.A. sits in the lower half of the current research and development expense sample.
Compared with
Compared with 57 companies reporting research and development expense in EUR. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 1x the current sample midpoint. Research And Development Expense is up about 15% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2017 to 31 Dec 2025.
- Nearby companies in this sample: MATERIALISE NV and CureVac N.V..
- Current sample position: rank #30 of 57 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Abivax S.A.: Research And Development Expense
Latest period: Q4 2025. Period end: 31 Dec 2025. Units: EUR. Frequency: quarterly and annual.
Research And Development Expense is an SEC-reported metric from company XBRL facts.
Metric Snapshot
- Latest value
- €44,399,000
- Coverage range
- 31 Dec 2021 - 31 Dec 2025
- Fact rows
- 13
What This Metric Tells You
- Shows the reported level of research and development expense over 31 Dec 2021 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 13 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
- Use the TTM line to smooth quarter-to-quarter noise.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Abivax S.A. appears at rank #30 in the latest comparison sample.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Stellantis N.V. (stla) | €11,145,000,000 | Year - 31 Dec 2025 | Open Stellantis N.V. Research And Development Expense |
| 2 | Sanofi (sny) | €7,842,000,000 | Year - 31 Dec 2025 | Open Sanofi Research And Development Expense |
| 3 | SAP SE (sap) | €6,633,000,000 | Year - 31 Dec 2025 | Open SAP SE Research And Development Expense |
| 4 | NOKIA CORP (nok) | €4,855,000,000 | Year - 31 Dec 2025 | Open NOKIA CORP Research And Development Expense |
| 5 | BioNTech SE (bntx) | €2,104,900,000 | Year - 31 Dec 2025 | Open BioNTech SE Research And Development Expense |
| 6 | KONINKLIJKE PHILIPS NV (phg) | €1,700,000,000 | Year - 31 Dec 2025 | Open KONINKLIJKE PHILIPS NV Research And Development Expense |
Metric Details
- Metric
- Research And Development Expense (ResearchAndDevelopmentExpense)
- Taxonomy
- ifrs-full
- Units tracked
- EUR
- Frequency coverage
- quarterly and annual
- History range
- 31 Dec 2021 - 31 Dec 2025
- Facts on this page
- 13
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Quarterly (EUR)
Research And Development Expense, YoY Quarterly Change (%)
Research And Development Expense, Annual (EUR)
Research And Development Expense, YoY Annual Change (%)
Abivax S.A. Quarterly Research And Development Expense (EUR)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | €177,761,000 | €44,399,000 | +€5,804,000 | +15% | 01 Oct 2025 | 31 Dec 2025 | 20-F | 23 Mar 2026 | 2025 | FY |
| Q3 2025 | €171,957,000 | €55,416,000 | +€12,130,000 | +28% | 01 Jul 2025 | 30 Sep 2025 | 6-K | 15 Dec 2025 | 2025 | Q3 |
| Q2 2025 | €159,827,000 | €38,645,000 | +€9,738,000 | +34% | 01 Apr 2025 | 30 Jun 2025 | 6-K | 08 Sep 2025 | 2025 | Q2 |
| Q1 2025 | €150,089,000 | €39,301,000 | +€3,557,000 | +10% | 01 Jan 2025 | 31 Mar 2025 | 6-K | 02 Jun 2025 | 2025 | Q1 |
| Q4 2024 | €146,532,000 | €38,595,000 | 01 Oct 2024 | 31 Dec 2024 | 20-F | 23 Mar 2026 | 2025 | FY | ||
| Q3 2024 | €43,286,000 | 01 Jul 2024 | 30 Sep 2024 | 6-K | 15 Dec 2025 | 2025 | Q3 | |||
| Q2 2024 | €28,907,000 | 01 Apr 2024 | 30 Jun 2024 | 6-K | 08 Sep 2025 | 2025 | Q2 | |||
| Q1 2024 | €35,744,000 | 01 Jan 2024 | 31 Mar 2024 | 6-K | 02 Jun 2025 | 2025 | Q1 |
Abivax S.A. Annual Research And Development Expense (EUR)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | €177,761,000 | +€31,229,000 | +21% | 01 Jan 2025 | 31 Dec 2025 | 20-F | 23 Mar 2026 | 2025 | FY |
| 2024 | €146,532,000 | +€43,356,000 | +42% | 01 Jan 2024 | 31 Dec 2024 | 20-F | 23 Mar 2026 | 2025 | FY |
| 2023 | €103,176,000 | +€54,881,000 | +114% | 01 Jan 2023 | 31 Dec 2023 | 20-F | 23 Mar 2026 | 2025 | FY |
| 2022 | €48,295,000 | +€514,000 | +1.1% | 01 Jan 2022 | 31 Dec 2022 | 20-F | 24 Mar 2025 | 2024 | FY |
| 2021 | €47,781,000 | 01 Jan 2021 | 31 Dec 2021 | 20-F | 05 Apr 2024 | 2023 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.